NETRIS PHARMA;Université Claude Bernard Lyon 1;Centre national de la recherche scientifique;Centre Léon-Bérard;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
发明人:
Benjamin DUCAROUGE,David GOLDSCHNEIDER,Anna Maria Rita REDAVID,Benjamin GIBERT,Patrick MEHLEN
申请号：
US16476239
公开号：
US20190315852A1
申请日:
2018.01.05
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The invention is the combination or combined use of (i) a compound able to disrupt or impede netrin-1/netrin-1 receptors interaction or netrin-1-mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.
